Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  This total is based on (i) 747,414 Ordinary Shares acquired by mDR Limited through subscription of the Issuer's Ordinary Shares between 2021 and 2022 for total consideration of approximately $1,185,449; (ii) 589,509 Ordinary Shares pursuant to the conversion in April 2023 of convertible loan (the "Convertible Loan") issued under the convertible loan agreement, dated December 10, 2019, by and between mDR Limited and CytoMed Therapeutics Pte. Ltd., as amended by supplemental agreements dated December 31, 2021, January 3, 2022 and January 3, 2023 (the "Convertible Loan Agreement"); and (iii) 28,990 Ordinary Shares sold between December 16, 2024 and January 6, 2025. The principal amount of the Convertible Loan was approximately $1,118,735.08 and the 589,509 Ordinary Shares were issued at approximately $1.89774 per share pursuant to the terms of the Convertible Loan. The foregoing consideration amount and price per share are based on an exchange rate of 1.3408 Singapore dollars to one United States dollar. Based on 11,540,000 of the Issuer's Ordinary Shares outstanding as of April 22, 2024, as disclosed on the Issuer's Annual Report on Form 20-F for the period ended December 31, 2023.


SCHEDULE 13G



 
mDR LTD
 
Signature:/s/ Edward Lee Ewe Ming
Name/Title:Executive Chairman
Date:03/24/2025